Andexanet Alfa
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Andexanet Alfa: From Factor Xa Inhibitor Reversal to Glanzmann Thrombasthenia
One-Sentence Summary
Andexanet Alfa (Ondexxya®) is a recombinant modified human Factor Xa decoy protein approved internationally as a reversal agent for life-threatening or uncontrolled bleeding in patients anticoagulated with direct Factor Xa inhibitors (apixaban, rivaroxaban). The TxGNN model predicts it may have potential in Glanzmann Thrombasthenia (TxGNN score: 99.77%), a rare inherited platelet aggregation disorder — however, the mechanistic analysis in this evidence pack flags this as a likely false-positive prediction arising from shared “bleeding disorder” phenotype nodes in the knowledge graph, with no supporting clinical trials and no supporting literature identified for this specific indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Reversal of anticoagulation by apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding |
| Predicted New Indication | Glanzmann Thrombasthenia |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data was not available in this evidence pack. Based on established pharmacological knowledge, Andexanet Alfa is a catalytically inactive recombinant modified human Factor Xa (FXa) protein. It acts as a competitive decoy by binding and sequestering Factor Xa inhibitors (apixaban, rivaroxaban) circulating in plasma, thereby restoring endogenous thrombin generation. This mechanism operates exclusively within secondary haemostasis — specifically the final common coagulation pathway — and has no interaction with platelet biology.
Glanzmann Thrombasthenia, by contrast, is a primary haemostasis disorder caused by deficiency or dysfunction of the platelet surface glycoprotein complex GPIIb/IIIa (integrin αIIbβ3). The pathology lies entirely in platelet aggregation failure, and standard treatments are platelet transfusion or recombinant activated Factor VIIa (rFVIIa). These two pathways — FXa inhibitor reversal and GPIIb/IIIa-mediated platelet aggregation — are biochemically independent with no known crossover points.
The mechanistic rationale provided in this evidence pack explicitly identifies this TxGNN prediction as a probable false positive, most likely resulting from co-localised “bleeding disorder” phenotype nodes in the knowledge graph creating a spurious connection, rather than any true biological or mechanistic similarity. This prediction should not be pursued without an independent credible biological hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for Glanzmann Thrombasthenia.
Contextual note — Hemophilia (TxGNN Rank 7, score 99.10%): This is the highest-ranked prediction with any literature support (11 publications, evidence level L4). However, none of these publications study andexanet alfa as a treatment for haemophilia. They primarily describe andexanet alfa in its approved role as a DOAC reversal agent, or address laboratory interference in haemophilia diagnostics. The table below is provided for context only and does not constitute evidence supporting a repurposing hypothesis.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33742436 | 2021 | Clinical Guideline | Thrombosis and Haemostasis | ICSH updated recommendations for DOAC laboratory measurement; references andexanet alfa as specific reversal agent for apixaban/rivaroxaban |
| 38620086 | 2024 | Observational Registry | Circulation | ANNEXA-4 subanalysis: andexanet alfa efficacy and safety in acute gastrointestinal bleeding in patients on FXa inhibitors |
| 30309890 | 2018 | Narrative Review | Blood | Review of andexanet alfa US licensure and the unmet clinical need for reversing FXa inhibitors in bleeding trauma patients |
| 31962376 | 2020 | Laboratory Study | Haemophilia | Andexanet alfa used to neutralise rivaroxaban interference in FVIII/FIX clotting assays; relevant to haemophilia A/B laboratory diagnosis |
| 36819179 | 2023 | Protocol Review | EJHaem | Review of UK hospital protocols for andexanet alfa use; practical implementation guidance |
| 31446606 | 2019 | Narrative Review | Internal and Emergency Medicine | Overview of reversal agents for DOAC-associated major or life-threatening bleeding including andexanet alfa |
| 31298165 | 2019 | Narrative Review | Current Pharmaceutical Design | New haemostatic agents in perioperative settings; includes andexanet alfa among procoagulant antidotes |
| 28277769 | 2017 | Narrative Review | Br J Hospital Medicine | Strategies for reversal of direct oral anticoagulants; early review including novel reversal agents |
| 26519420 | 2016 | Narrative Review | Drug Safety | NOAC reversal strategies — state of development and future perspectives |
| 39715914 | 2025 | Drug Approval Review | Drugs | Marstacimab (anti-TFPI antibody) first approval for haemophilia A/B; contextualises novel haemostatic mechanisms in haemophilia — distinct from andexanet alfa’s mechanism |
Denmark Market Information
Andexanet Alfa is not currently authorised or marketed in Denmark. No marketing authorisations from Laegemiddelstyrelsen (national procedure) or via the EMA centralised procedure have been registered for use in Denmark at the time of this report.
| Marketing Authorisation | Product Name | Status | Note |
|---|---|---|---|
| EU/1/19/1376 (EMA) | Ondexxya® (AstraZeneca) | Centrally authorised in EU — not registered in Denmark | Approved for reversal of apixaban/rivaroxaban in life-threatening bleeding in adults |
If access is required in Denmark, a Named Patient Programme or hospital exemption import application to Laegemiddelstyrelsen would be the applicable pathway, referencing the EMA-approved Ondexxya® SmPC.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for Ondexxya® (EU/1/19/1376) for complete safety information.
Safety data (key warnings, contraindications, drug-drug interactions) were not available in this evidence pack. Clinicians should be aware that andexanet alfa carries a known risk of thromboembolic events (including stroke, myocardial infarction, and deep vein thrombosis) associated with its pro-coagulant reversal mechanism. Full risk-benefit assessment is required for each individual patient.
Conclusion and Next Steps
Decision: Hold
Rationale: The top TxGNN prediction of Glanzmann Thrombasthenia carries an evidence level of L5 (model prediction only, no clinical or preclinical studies) and the embedded mechanistic rationale explicitly identifies this as a biological implausibility — Andexanet Alfa’s FXa-decoy mechanism targets secondary haemostasis (the coagulation cascade), while Glanzmann Thrombasthenia is a primary haemostasis disorder (platelet aggregation failure via GPIIb/IIIa deficiency) with no mechanistic overlap. All other predicted indications in this pack (platelet release disorders, pseudo-von Willebrand disease, hemophilia) similarly lack supporting clinical trial evidence and do not have a credible mechanistic basis for repurposing.
To proceed, the following would be needed:
- An independent credible biological hypothesis linking andexanet alfa’s FXa-decoy mechanism to platelet biology or any of the predicted bleeding disorders
- Preclinical evidence (in vitro models or animal studies) demonstrating pharmacological activity relevant to the proposed new indication
- Expert haematology consultation to evaluate biological plausibility before any clinical exploration
- Complete SmPC and safety profile review, including thromboembolic risk assessment, before any clinical consideration
- Resolution of the data gap regarding the full mechanism of action (DrugBank API query recommended per DG002)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.